This article is more than 5 years old. Information may no longer be current.

Anthem Blue Cross Blue Shield to cover Avedro’s corneal cross-linking

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Anthem Blue Cross Blue Shield will cover Avedro’s Photrexa formulations and KXL System for corneal cross-linking, the company announced in a press release.

This brings the number of commercial payers covering the procedure to 60, including the U.S.’s largest payers United Healthcare, Anthem Blue Cross Blue Shield, Aetna, Cigna, Humana and HealthNet, the release said.

“In the past month alone, our Photrexa drug formulations were issued a permanent J code from CMS, and we added an additional 40 million lives who can access cross-linking,” Avedro CEO Reza Zadno, PhD, said in the release. “Our goal is to ensure cross-linking is accessible to every patient struggling with progressive keratoconus. Reaching these milestones brings us increasingly closer to this goal.”